Here's Why You Should Add Ingevity Stock to Your Portfolio

Ingevity Corporation’s NGVT stock looks promising at the moment. NGVT is expected to benefit from the strategic repositioning of its Performance Chemicals segment, strategic acquisitions and actions to drive growth.

We are positive about the company’s prospects and believe that the time is right for you to add the stock to your portfolio as it is poised to carry the momentum ahead.

Let's see what makes NGVT stock an attractive investment option at the moment.

Ingevity’s Strong Growth Prospects

The Zacks Consensus Estimate for NGVT’s 2025 earnings is pegged at $4.45, suggesting a 26.8% increase from the previous year’s tally. Earnings are projected to increase by 18% in 2026.

NGVT’s Positive Earnings Surprise History

Ingevity has outpaced the Zacks Consensus Estimate in three of the trailing four quarters. In this time frame, it has delivered an earnings surprise of roughly 202.9%, on average.

Ingevity’s Superior Return on Equity (ROE)

ROE is a measure of a company’s efficiency in utilizing shareholders’ funds. ROE for the trailing 12-months for Ingevity is 41.4%, above the industry’s level of 18.8%.

Strategic Repositioning and Acquisitions to Aid NGVT

Ingevity is taking several actions to expand capacity and drive long-term growth. It remains committed to investing organically. Ingevity is also committed to capturing the maximum value for its products.

The company is expected to benefit from the repositioning of its Performance Chemicals segment, which is aimed at lowering exposure to lower-margin end markets. The move includes consolidating segment operations at its North Charleston facility by moving oleo chemical refining to the North Charleston site’s secondary refinery as well as the closure of its Crossett facility. These actions further simplify the segment’s manufacturing footprint and create significant cost savings. NGVT realized roughly $84 million of savings from repositioning actions in 2024. It sees around $10-$25 million in incremental savings in 2025.

Ingevity remains focused on enhancing shareholder value through improved EBITDA, improving margins and strong cash flows. The company is seeing the benefits of the repositioning on its earnings and cash flows. Operational improvements leading to lower input costs and better manufacturing efficiency are also aiding performance in its Performance Materials unit. 

The acquisition of the Capa caprolactone business enabled the company with a new technology platform to drive revenue and earnings growth. Capa has a strong and market-leading business that focuses on high-growth end-use applications. NGVT, in July 2024, expanded its Capa caprolactone distribution network by selecting Ultrapolymers Group as the distributor for Capa Bioplastics in Europe. The acquisition of Ozark Materials has also strengthened the company’s position in the paving construction industry.

Ingevity Corporation Price and Consensus

Ingevity Corporation price-consensus-chart | Ingevity Corporation Quote

NGVT’s Zacks Rank & Other Key Picks

NGVT currently carries a Zacks Rank #1 (Strong Buy).

Other top-ranked stocks in the Basic Materials space are Axalta Coating Systems Ltd. AXTA, CSW Industrials Inc. CSWI and Carpenter Technology Corporation CRS. While AXTA sports a Zacks Rank #1, CSWI and CRS carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Axalta Coating’s 2025 earnings is pegged at $2.54, indicating a rise of 12.5% from year-ago levels. AXTA beat the consensus estimate in each of the trailing four quarters. In this time frame, it has delivered an earnings surprise of roughly 16.3%, on average. 

The Zacks Consensus Estimate for CSW Industrials’ current fiscal-year earnings is pegged at $8.50, suggesting a 21.3% year-over-year increase. CSWI surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average earnings surprise of 10.1%. 

The consensus estimate for Carpenter Technology for the current fiscal year stands at $6.95, reflecting a 46.6% year-over-year increase. CRS beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 15.7%. 

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research